Qingweishi (Everolimus) 2.5mg Tablets | First Chinese Generic | GLT

Generic Information: Qingweishi (Everolimus) — First Chinese Generic

Qingweishi (晴维时) is the first domestically developed generic of everolimus in China, produced by CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CTTQ), a leading Chinese innovative pharmaceutical company. This page covers the 2.5 mg × 30-tablet pack. Qingweishi earned a landmark regulatory distinction: it was approved as China's first generic everolimus and, as the first product to successfully challenge the originator patent under China's drug patent linkage system, received a 12-month market exclusivity period. That makes Qingweishi a significant, quality-assured domestic alternative to the Novartis originator.

What Is Qingweishi (Everolimus) Used For?

Qingweishi (everolimus) is approved for the same indications as the originator: advanced renal cell carcinoma after sunitinib or sorafenib failure, progressive pancreatic neuroendocrine tumors, non-functional gastrointestinal or lung neuroendocrine tumors, TSC-associated renal angiomyolipoma and subependymal giant cell astrocytoma, and hormone receptor-positive, HER2-negative advanced breast cancer in combination with exemestane. The 2.5 mg strength is particularly useful for low-dose initiation and for patients requiring reduced dosing.

How Does Qingweishi (Everolimus) Work?

As a generic, Qingweishi is bioequivalent to the originator Afinitor, meaning it delivers the same everolimus exposure in the body. Everolimus inhibits mTORC1 by binding FKBP-12, reducing the phosphorylation of S6K1 and 4E-BP1 and thereby slowing tumor cell proliferation, protein synthesis, and angiogenesis. CTTQ completed its bioequivalence study in 2018 and submitted the application under the generic pathway, confirming Qingweishi matches the originator's pharmacokinetic profile.

Indications

Qingweishi is indicated for: (1) advanced renal cell carcinoma in adults who have progressed on sunitinib or sorafenib; (2) unresectable, locally advanced or metastatic, well-differentiated progressive pancreatic neuroendocrine tumors; (3) progressive, well-differentiated, non-functional GI or lung neuroendocrine tumors; (4) TSC-associated renal angiomyolipoma; (5) TSC-associated SEGA; and (6) hormone receptor-positive, HER2-negative advanced breast cancer combined with exemestane.

Dosage

The recommended dose is 10 mg once daily, with the 2.5 mg tablet used for low-dose initiation or dose reduction. Qingweishi tablets should be swallowed whole with water, with or without food, at the same time each day. Dosage should be adjusted by the treating physician based on liver function, drug interactions, and tolerability.

Side Effects

The side-effect profile of Qingweishi matches that of everolimus generally: stomatitis, rash, fatigue, diarrhea, infections, and metabolic changes such as hyperglycemia and elevated lipids are most common. Patients should be monitored for non-infectious pneumonitis and renal function, and should report persistent mouth sores or new respiratory symptoms promptly.

Storage

Store Qingweishi tablets in the original packaging below 30°C, protected from moisture and light. Keep out of reach of children and do not use beyond the expiry date.

Why Choose the GLT?

Qingweishi represents the highest-quality domestic generic of everolimus, backed by CTTQ's bioequivalence data and its first-to-market status under China's patent linkage system. As a Hong Kong-licensed supplier, GLT provides a dependable channel for this China-made generic alongside the originator, with full batch documentation and transparent pricing. For buyers seeking a lower-cost everolimus that is still manufactured to Chinese GMP standards and bioequivalent to Afinitor, Qingweishi is an excellent option.

How to Order Qingweishi (Everolimus)

To order Qingweishi, contact our team on WhatsApp at +86 15234153837 or by email at [email protected]. Please share the required quantity and your destination country so we can confirm availability, documentation, and delivery terms.

FAQ

Is Qingweishi a generic of Afinitor? Yes. Qingweishi (晴维时) is the first domestically developed generic of everolimus in China, bioequivalent to the Novartis originator Afinitor.

Who makes Qingweishi? Qingweishi is produced by CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CTTQ), a major Chinese pharmaceutical company.

What strengths are available? Qingweishi is available in 2.5 mg tablets (30 per pack), with other strengths also supplied by the manufacturer.

Why was Qingweishi significant at launch? It was China's first generic everolimus and the first product to gain a 12-month market exclusivity period under China's drug patent linkage system.